Robert LeBoyer
Stock Analyst at Noble Capital Markets
(1.16)
# 3,822
Out of 5,131 analysts
18
Total ratings
31.25%
Success rate
-0.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert LeBoyer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNXP Tonix Pharmaceuticals Holding | Reiterates: Outperform | $70 | $15.48 | +352.20% | 2 | Mar 20, 2025 | |
| NTRB Nutriband | Initiates: Outperform | $13 | $4.37 | +197.48% | 1 | Jan 22, 2025 | |
| GOVX GeoVax Labs | Maintains: Outperform | $6 → $10 | $0.17 | +5,938.65% | 2 | Aug 19, 2024 | |
| UNCY Unicycive Therapeutics | Initiates: Outperform | $60 | $6.18 | +870.87% | 1 | Feb 14, 2024 | |
| CVKD Cadrenal Therapeutics | Initiates: Outperform | $60 | $8.17 | +634.39% | 1 | Dec 18, 2023 | |
| ELDN Eledon Pharmaceuticals | Initiates: Outperform | $10 | $1.73 | +478.03% | 1 | Sep 27, 2023 | |
| MAIA MAIA Biotechnology | Initiates: Outperform | $14 | $1.63 | +758.90% | 1 | Feb 21, 2023 | |
| LCTX Lineage Cell Therapeutics | Initiates: Outperform | $8 | $1.71 | +367.84% | 2 | Aug 19, 2021 | |
| PSTV Plus Therapeutics | Initiates: Buy | $120 | $0.56 | +21,513.83% | 1 | Jan 25, 2021 | |
| BNTC Benitec Biopharma | Downgrades: Neutral | n/a | $11.84 | - | 1 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.28 | +180.37% | 1 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9,900,000 | $5.82 | +170,102,992.78% | 1 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $35.58 | - | 1 | Apr 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $3.41 | +339.88% | 2 | Mar 8, 2018 |
Tonix Pharmaceuticals Holding
Mar 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $15.48
Upside: +352.20%
Nutriband
Jan 22, 2025
Initiates: Outperform
Price Target: $13
Current: $4.37
Upside: +197.48%
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $6 → $10
Current: $0.17
Upside: +5,938.65%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $60
Current: $6.18
Upside: +870.87%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $8.17
Upside: +634.39%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $1.73
Upside: +478.03%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $1.63
Upside: +758.90%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $1.71
Upside: +367.84%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $120
Current: $0.56
Upside: +21,513.83%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $11.84
Upside: -
Sep 28, 2020
Initiates: Buy
Price Target: $12
Current: $4.28
Upside: +180.37%
Aug 24, 2020
Initiates: Buy
Price Target: $9,900,000
Current: $5.82
Upside: +170,102,992.78%
Apr 10, 2018
Downgrades: Neutral
Price Target: n/a
Current: $35.58
Upside: -
Mar 8, 2018
Initiates: Buy
Price Target: $15
Current: $3.41
Upside: +339.88%